Latest News

Page 14 of 28« First...1213141516...20...Last »

November 6, 2014

Study May Lead to More Accurate Long-Term Prediction of Wet AMD

Posted in: Latest News, Research and Developments

Stanford University School of Medicine scientists have found a new way to forecast which patients with age-related macular degeneration (AMD) are likely to progress to the advanced wet form of the disease. Until now, there has been no effective way to to do this. The new method predicts whether a patient’s vision would, if untreated, probably
read more »

October 31, 2014

Stem Cells Might Now Replace Photoreceptors

Posted in: Latest News, Research and Developments

The media has been full of news about sight restoration from stem cells. In trials, stem cells are healing the retinal layer (retinal pigment epithelium) that supports the nerve cells (photoreceptors) responsible for seeing light. Scientists, however, have not yet been able to replace damaged photoreceptor cells in humans, but a recent study offers hope
read more »

October 22, 2014

“Hubble Lens” May Be Next IOL For AMD

Posted in: Latest News, Research and Developments

by Dan Roberts London Eye Hospital Pharma announced today that it has initiated U.S. discussions to gain clinical data for its iolAMD lens system.  iolAMD is a novel intraocular lens (IOL) system designed to restore lost vision and provide an independent lifestyle for patients with dry AMD and related diseases. The technology behind the iolAMD lens
read more »

October 16, 2014

Study Shows No Difference Between Tinted and Clear IOLS

Posted in: Latest News, Research and Developments

by Dan Roberts For several years, eye doctors have been debating the value of tinted intraocular lenses (IOLs) in eyes that have undergone cataract surgery. Those in favor of them argue that they reduce the retina’s exposure to potentially hazardous ultraviolet and blue light. The main argument against them is that they cause a decrease
read more »

October 15, 2014

Stem Cell Trial Yields Surprising Results

Posted in: Latest News, Research and Developments

by Dan Roberts Advanced Cell Technology, Inc. (now owned by Astellas) has been conducting promising safety trials for stem cell treatment of macular degeneration, but a six-month follow up has yielded even better news than expected. ACT announced that Phase 1/2 clinical data treatment of Stargardt’s macular degeneration (SMD) and dry age-related macular degeneration (AMD). Surprising even
read more »

October 9, 2014

FDA Grants Priority Review for Lucentis in Diabetic Retinopathy

Posted in: Latest News

Genentech has announced that the FDA has granted its submission for Priority Review of Lucentis® (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans. The FDA confirmed action date is February 6, 2015. If approved, Lucentis could be the first eye medicine available for diabetic retinopathy patients. Lucentis
read more »

October 3, 2014

Opportunity to Share Your AMD Experience

Posted in: Latest News

If you or a loved one has Advanced Dry Macular Degeneration (AMD)/Geographic Atrophy (GA), we want to hear from you. Genentech, a leading biotechnology corporation, is looking for people who suffer from or who have a loved one who lives with AMD/GA to share their personal experiences in an upcoming focus group. Travel and lodging
read more »

September 30, 2014

FDA Approves Two Extended-Release Drug Therapies For DME

Posted in: Latest News, Therapies, Treatments, and Procedures

By Dan Roberts Implants devised by two different companies for treatment of diabetic macular edema (DME) have been approved by the FDA for use in the United States. The companies are Allergan and Alimera, and the new drugs are Ozurdex and Iluvien respectively. Both drugs are corticosteroids that have demonstrated effectiveness in the treatment of
read more »

September 25, 2014

Final Stargardt Patient Treated In Initial Stem Cell Trial

Posted in: Latest News

Advanced Cell Technology (ACT) has treated the final patient in the UK-based Phase 1 clinical trial evaluating the safety and tolerability of the company’s stem cell therapy for Stargardt’s disease. To date, no adverse events have been reported. The company is working with U.S. and European regulators to commence a Phase 2 trial to assess
read more »

September 23, 2014

Gene Profiling Technique Accelerates Stem Cell Therapies for Retinal Diseases

Posted in: Latest News, Research and Developments

(Source: National Eye Institute, National Institutes of Health) Researchers at the National Institutes of Health have developed a technique that will streamline the production of stem-cell derived tissues. The technique will help the researchers in their efforts to use patients’ skin cells to create new retinal tissue, a therapy that has been recently applied to
read more »

Page 14 of 28« First...1213141516...20...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann